Summary of Ionis Pharmaceuticals FY Conference Call Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **Focus**: Genetic medicines targeting RNA for clinically meaningful diseases with high unmet needs - **Year Ahead**: 2026 is expected to be a transformational year with significant momentum from 2025 [3][4] Key Product Launches and Financial Performance - **TRYNGOLZA**: - First FDA-approved medicine for familial chylomicronemia syndrome (FCS) - Generated $108 million in total revenue in 2025, exceeding estimates [4] - Strong quarter-over-quarter growth and positive patient feedback [9] - **DAWNZERA**: - Approved for hereditary angioedema, also showing a good start post-launch [4] - **Severe Hypertriglyceridemia (SHTG)**: - Upcoming launch in July 2026, with priority review from the FDA [6] - Expected to significantly increase patient population from 3,000 (FCS) to 3 million (SHTG) [11] - Anticipated peak product sales of over $2 billion in the U.S. [17] Clinical Developments and Pipeline - **Alexander Disease**: - Positive Phase 3 data expected to lead to approval and launch in fall 2026 [7] - **Partnered Pipeline**: - Five Phase 3 readouts expected in 2026, including studies for ATTR cardiomyopathy and Lp(a) cardiovascular disease [7] - **ATTR Cardiomyopathy**: - Estimated 500,000 patients in the U.S. with high unmet needs [25] - Potential peak product sales of over $5 billion for eplontersen, a silencer drug [28] - **Lp(a) Cardiovascular Disease**: - Phase 3 study (HORIZON) expected to read out in the second half of 2026, aiming for significant reductions in Lp(a) levels [34][35] Pricing Strategy and Market Considerations - **Pricing for SHTG**: - Initial pricing strategy to transition from a rare disease price to a specialty price, with a focus on maximizing patient access [11][12] - Estimated net price range of $10,000-$20,000 for SHTG [12] - **Market Dynamics**: - Facing pricing pressure from competitors, but managing effectively [10][20] - Anticipated revenue dip initially due to pricing adjustments, with expected recovery in the second half of 2026 [22][18] Research and Development Insights - **Tau Program with Biogen**: - Focus on tau targeting for neurodegenerative diseases, with positive Phase 1, 2 data indicating potential cognitive improvements [39] - **Angelman's Syndrome**: - Rare disease with no effective treatments; Ionis is optimistic about its drug ION582 based on strong early clinical data [40][42] Conclusion - Ionis Pharmaceuticals is positioned for significant growth in 2026 with multiple product launches and a robust pipeline. The company is navigating market challenges while focusing on maximizing patient access and addressing high unmet medical needs across its therapeutic areas [43][44]